The global renal biomarkers market reached a value of US$ 1.13 billion in 2021. Looking forward, the market is projected to reach a value of US$ 1.88 billion by 2027, exhibiting a CAGR of 8.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, the analyst is continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different End-use sectors. These insights are included in the report as a major market contributor.
Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
Chronic kidney disease (CKD), non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension and heart diseases. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market. Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market.
This report provides an analysis of the key trends in each sub-segment of the global renal biomarkers market, along with forecasts at the global, regional and country level from 2022-2027. The report has categorized the market based on biomarker type, diagnostic technique and End-user.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.
Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.
Renal Biomarkers Market Trends
Chronic kidney disease (CKD), non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension and heart diseases. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market. Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global renal biomarkers market, along with forecasts at the global, regional and country level from 2022-2027. The report has categorized the market based on biomarker type, diagnostic technique and End-user.
Breakup by Biomarker Type:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-regulated Protein
- Neutrophil Gelatinase-Associated Lipocalin (NGAL)
- Kidney Injury Molecule-1
- INTERLEUKIN-18
- Others
Breakup by Diagnostic Technique:
- Enzyme-linked Immunosorbent Assay (ELISA)
- Particle-enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography Mass Spectrometry (LC-MS)
Breakup by End-user:
- Hospital
- Diagnostic Laboratory
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report
- How has the global renal biomarkers market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global renal biomarkers market?
- What are the key regional markets?
- What is the breakup of the market based on the biomarker type?
- What is the breakup of the market based on the diagnostic technique?
- What is the breakup of the market based on the End-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global renal biomarkers market and who are the key players?
- What is the degree of competition in the industry?
Frequently Asked Questions about the Global Renal Biomarkers Market
What is the estimated value of the Global Renal Biomarkers Market?
What is the growth rate of the Global Renal Biomarkers Market?
What is the forecasted size of the Global Renal Biomarkers Market?
Who are the key companies in the Global Renal Biomarkers Market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Renal Biomarkers Market
6 Market Breakup by Biomarker Type
7 Market Breakup by Diagnostic Technique
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Beckman Coulter Inc. (Danaher Corporation)
- bioMérieux SA
- BioPorto A/S
- Bio-Rad Laboratories Inc.
- Enzo Biochem Inc.
- F. Hoffmann-La Roche AG
- PerkinElmer Inc.
- Randox Laboratories Ltd.
- Siemens AG
- Thermo Fisher Scientific Inc
Methodology
LOADING...
